Samsung Bioepis, Proteina to Develop AI Antibody Drugs

Takeda signs $600M AI drug discovery deal with Insilico

Lundbeck partners with AI firm Cradle for antibody development in neurological disorders

Danish pharmaceutical company Lundbeck has partnered with AI firm Cradle to use its artificial intelligence software for designing two antib

How AI Will Transform Biopharma: The Sequence of Change Matters

Ben Liu, CEO of Formation Bio, argues that AI will transform the pharmaceutical industry unevenly and sequentially. Some parts of drug disco

Alp Bio's AI platform predicts immune reactions to biologic drugs in early development

An interview with Christian Vahlensieck, co-founder of Alp Bio, a Swiss startup using an AI-powered platform combined with lab-grown human i

Alp Bio's AI platform predicts immune reactions to biologic drugs earlier in development

An interview with Christian Vahlensieck, co-founder of Alp Bio, a Swiss startup using an AI-powered platform combined with lab-grown human i

AI-Driven Protein Binder Design: Progress and Pitfalls in Evaluation Practices

This article discusses the rapid advancement of de novo protein binder design using AI, including antibodies and nanobodies. While the field